View Older Stories View More Recent Stories

May 20, 2024 08:30AM Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
May 15, 2024 04:01PM Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
May 8, 2024 04:01PM Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
Apr 25, 2024 04:01PM Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
Mar 7, 2024 04:01PM Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
Feb 26, 2024 09:00AM Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
Feb 22, 2024 08:31AM Arcturus Therapeutics (ARCT) Granted EU Orphan Medicinal Product Designation for ARCT-032
Feb 22, 2024 08:30AM Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
Feb 20, 2024 09:00AM Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
Feb 5, 2024 08:31AM Arcturus Therapeutics (ARCT) Reports New COVID-19 sa-mRNA Results Demonstrate Longer Duration of Immunity
Feb 5, 2024 08:30AM New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Jan 5, 2024 01:18PM Arcturus Therapeutics (ARCT) and PassPort Technologies Commences Research to Evaluate Transdermal mRNA delivery systems
Jan 5, 2024 01:17PM PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems
Dec 21, 2023 08:00AM CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Dec 21, 2023 08:00AM CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Dec 4, 2023 08:30AM Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nov 28, 2023 08:06AM Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' (ARCT) ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Nov 28, 2023 08:05AM Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Nov 28, 2023 08:00AM Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
Nov 27, 2023 08:31AM Arcturus Therapeutics (ARCT) Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
Nov 27, 2023 08:30AM Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
Nov 14, 2023 04:01PM Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
Oct 25, 2023 04:01PM Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
Oct 23, 2023 04:01PM Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
Oct 4, 2023 08:31AM Arcturus Therapeutics (ARCT) JV mRNA Manufacturing Partner ARCALIS Awarded Additional Financial Grants from Japanese Government
Oct 4, 2023 08:30AM Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government
Sep 26, 2023 08:30AM Arcturus Therapeutics (ARCT) and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032
Sep 26, 2023 08:30AM Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
Sep 19, 2023 08:30AM Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
Sep 5, 2023 08:34AM Arcturus Therapeutics (ARCT) and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154
Sep 5, 2023 08:30AM Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
Aug 17, 2023 08:30AM Arcturus Therapeutics to Attend Upcoming Investor Conferences
Aug 14, 2023 09:00AM Arcturus Therapeutics' (ARCT) Partner ARCALIS Wins $115M in Grants from the Japanese Government
Aug 14, 2023 09:00AM Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
Aug 7, 2023 04:01PM Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
Jul 24, 2023 04:01PM Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
Jun 1, 2023 08:30AM Arcturus Therapeutics (ARCT) Granted FDA Fast Track Designation for ARCT-810
Jun 1, 2023 08:30AM Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
Apr 26, 2023 08:30AM Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
Mar 28, 2023 04:01PM Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
Mar 7, 2023 08:00AM Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023
Feb 6, 2023 08:30AM Arcturus Therapeutics to Attend Upcoming Investor Conferences
Jan 31, 2023 08:30AM Arcturus Therapeutics (ARCT) Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Jan 31, 2023 08:30AM Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Dec 19, 2022 08:30AM Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 13, 2022 08:37AM Arcturus Therapeutics (ARCT) names John Markels to board
Dec 13, 2022 08:30AM Arcturus Appoints John Markels, Ph.D. to its Board of Directors
Dec 12, 2022 08:30AM CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
Nov 9, 2022 04:01PM Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
Nov 9, 2022 08:00AM Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
View More Recent Stories View Older Stories